Results 91 to 100 of about 39,529 (215)

Outcomes and Risk Factors in Oncologic Temporal Bone Surgery: A Head and Neck‐Specific NSQIP Analysis

Otolaryngology–Head and Neck Surgery, Volume 174, Issue 3, Page 774-783, March 2026.
Abstract Objective Advanced temporal bone and parotid gland malignancies are rare and difficult to manage. However, complications of oncologic temporal bone surgery have not been systematically categorized. We aim to detail the postoperative outcomes of lateral temporal bone resection (LTBR) and mastoidectomy for otologic oncology patients, and ...
Bailey H. Duhon, Xiaowen Sun, Mike Hernandez, Carol M. Lewis, Marc‐Elie Nader, Paul W. Gidley   +5 more
wiley   +1 more source

Comparative efficacy of certoparin, enoxaparin, and combined thromboprophylaxis on thromboembolic events after glioblastoma resection: a prospective observational study

Scientific Reports
Thromboembolic events (TE) are serious complications following glioblastoma (GBM) resection. This retrospective study analyzed 695 GBM patients (2017–2022, University Hospital Dresden) to assess the impact of different anticoagulant regimens—certoparin ...
Eva Wardenbach, Dino Podlesek, Boshr Alhasan, Ahmed Abouelhamd, Ilker Y. Eyüpoglu, Tareq A. Juratli, Witold H. Polanski   +6 more
doaj   +1 more source

Clinical and Laboratory Impact of Postpartum Enoxaparin Prophylaxis After Vaginal Delivery: A Retrospective Cohort Study

Cam & Sakura Medical Journal
Objective: To assess the clinical and laboratory effects of prophylactic enoxaparin use after vaginal delivery on bleeding, wound complications, and hematological parameters.
Emrah Dağdeviren, Ali Selçuk Yeniocak, Can Tercan, Şeyda Büyük, Nisa Sarı, Elif Ataseven, Yücel Kaya, Gazi Güner   +7 more
doaj   +1 more source

In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin.

PLoS ONE, 2015
BackgroundEnoxaparin, a mixture of anticoagulant and non-anticoagulant fractions, is widely used as an anticoagulant agent. However, it is also reported to possess anti-inflammatory properties.
Madhur D Shastri, Niall Stewart, James Horne, Gregory M Peterson, Nuri Gueven, Sukhwinder S Sohal, Rahul P Patel   +6 more
doaj   +1 more source

Apixaban and oral implications [PDF]

, 2015
Background: Thrombotic disorders remain a leading cause of death in the Western world, and in this regard a number of anticoagulation treatment have been used, including heparins, fondaparinux, vitamin K antagonists ...
Bagán Sebastián, José Vicente, López Galindo, Mónica Paula   +1 more
core   +1 more source

Low‐Molecular‐Weight Heparin for Adult ICU Patients Who Require Thromboprophylaxis: Protocol for the INCEPT‐Thromboprophylaxis Platform Trial Domain

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 3, March 2026.
ABSTRACT Background Low‐molecular‐weight heparin (LMWH) is recommended for thromboprophylaxis in adult intensive care unit (ICU) patients. Despite its widespread use, there is insufficient evidence on the optimal dose, and there appears to be practice variation.
Ruben Eck, Anders Granholm, Aske Tøgern, Aksel Karl Georg Jensen, Sandra Jonmarker, Fredrik Sjövall, Karina Meijer, Maria Cronhjort, Morten Hylander Møller, Anders Perner, Frederik Keus   +10 more
wiley   +1 more source

Update on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients

Medicina
Low-molecular-weight heparins are a class of drugs derived from the enzymatic depolymerization of unfractionated heparin that includes enoxaparin. Several studies have been performed on enoxaparin in recent years, in particular for the prevention and ...
Egidio Imbalzano, Luana Orlando, Giuseppe Dattilo, Marianna Gigliotti De Fazio, Giuseppe Camporese, Vincenzo Russo, Alessandro Perrella, Francesca Futura Bernardi, Pierpaolo Di Micco   +8 more
doaj   +1 more source

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients [PDF]

, 2006
Background Clinical trials have shown low-molecular weight heparin (LMWH) to be at least as safe and efficacious as unfractionated heparin (UFH) for preventing venous thromboembolism (VTE) in acutely-ill medical inpatients.
Lisa J McGarry, Michael E Stokes, David Thompson   +2 more
core   +1 more source

Evaluation of the Enhanced Recovery After Surgery (ERAS) Guidance for Patients With Spinal Metastasis

Orthopaedic Surgery, Volume 18, Issue 3, Page 385-401, March 2026.
The flow diagram of study. ABSTRACT Surgery continues to remain the most effective treatment for spinal metastasis (SM). As the number of surgeries continues to grow, the need for consensus guidelines for optimal perioperative care is imperative. Enhanced recovery after surgery (ERAS) protocols were created for this purpose. The objective of this study
Fanjie Li, Wenlong Yu, Changchang Shen, Jinxin Luo, Zhibin Li, Qiang Gao, Chengchun Jin, Tao Li, Quan Huang, Shuqiang Wang, Peilin Chu, Mengchen Yin   +11 more
wiley   +1 more source

Thromboembolism After Intramedullary Nailing for Metastatic Bone Lesions. [PDF]

, 2015
BACKGROUND: The risk of venous thromboembolism (VTE) in patients undergoing intramedullary nailing for skeletal metastatic disease is currently undefined.
Abraham, John A, Geller, David S, Greenbaum, Simon, Lee, Alan, Maltenfort, PhD, Mitchell, Merli, Geno J, Ready, John, Shallop, Brandon, Starks, Alexandria   +8 more
core   +2 more sources